Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2008-01-21
2011-11-15
Cheu, Jacob (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007200, C436S518000
Reexamination Certificate
active
08058015
ABSTRACT:
The present invention relates to a method for the determination or prediction of the progression of chronic kidney disease in a subject suspected to suffer from chronic kidney disease, said method comprising the step of determining the expression levels of at least one marker selected from (a) FGF23; and (b) adiponectin in a biological sample. Furthermore, the present invention relates to a use of a specific detection molecule for FGF23 or use of a specific detection molecule for adiponectin for the preparation of a diagnostic composition for the detection of chronic kidney disease or the progression of chronic kidney diseases in a subject suspected to suffer from said disease. In particular, the present invention also provides for use of FGF23 and/or of adiponectin as an in vitro marker for the presence, absence or progression of a chronic kidney disease and kits comprising a specific detection molecule for FGF23 or a specific detection molecule for adiponectin for use in the method of the present invention.
REFERENCES:
patent: 2005/0004348 (2005-01-01), Miyamoto et al.
patent: WO 02/08271 (2002-01-01), None
Komaba et al. (Am J. Nephrol. 2006 vol. 26, p. 476-482).
Haiman et al. (Kidney International. 2005 vol. 68, p. 1130-1136).
Fliser et al., “Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: themild to moderate kidney disease (MMKD) study,”J. Am. Soc. Nephrol., 18: 2601-2608, 2007.
Guebre-Egziabher et al., “Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function,”Nephrol. Dial. Transplant, 20: 129-134, 2005.
Gutierrez et al., “Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease,”J. Am. Soc. Nephrol., 16: 2205-2215, 2005.
Iwashima et al., “Adiponectin and renal funciton, and implication as a risk of cardiovascular disease,”Am. J. Cardiology, 98: 1603-1608, 2006.
Koiwa et al., “Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients,”Therapeutic Apheresis and Dialysis, 9 (4): 336-339, 2005.
Larsson et al., “Circulating concentration of FGF-23 increases as renal funciton declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers,”Kidney International, 64: 2272-2279, 2003.
Menon et al., “Adiponectin and mortality in patients with chronic kidney disease,”J. Am. Soc. Nephrol., 17: 2599-2606, 2006.
PCT, International Search Report issued in Int. App. No. PCT/EP2008/000420, mailed Jul. 1, 2008.
Shen et al., “Up-regulation of adiponectin, its isoforms and receptors in end-stage kidney disease,”Nephrol. Dial. Transplant, 22: 171-178, 2007.
International Preliminary Report on Patentability, issued in Int. App. No. PCT/EP2008/000420, mailed Jul. 28, 2009.
Fliser Danilo
Kollerits Barbara
Kronenberg Florian
Cheu Jacob
Fulbright & Jaworski L.L.P.
Medizinische Universität Innsbruck
LandOfFree
Markers for chronic kidney disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Markers for chronic kidney disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Markers for chronic kidney disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4284695